|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent PLx Pharma insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why PLx Pharma insider buys are important for investors to follow.
Date | Insider | Price | Amount |
3-15-2022 Insider Buy |
Rita M. O'connor Chief Financial Officer |
$3.66
CAGR »
|
$50,122.02 13,700 shares |
3-15-2022 Insider Buy |
Natasha Giordano Chief Executive Officer |
$3.65
CAGR »
|
$14,976.89 4,100 shares |
6-14-2021 Insider Buy |
Michael J. Valentino Executive Chairman |
$12.48
CAGR »
|
$99,870.35 8,000 shares |
3-5-2021 Insider Buy |
Michael J. Valentino Executive Chairman |
$8.00
CAGR »
|
$200,000.00 25,000 shares |
12-14-2020 Insider Buy |
John Hadden Director |
$5.45
CAGR »
|
$5,447.96 1,000 shares |
11-25-2020 Insider Buy |
John Hadden Director |
$5.48
CAGR »
|
$2,737.85 500 shares |
9-2-2020 Insider Buy |
Rita M. O'connor Chief Financial Officer |
$3.77
CAGR »
|
$24,963.80 6,620 shares |
8-21-2020 Insider Buy |
Rita M. O'connor Chief Financial Officer |
$3.90
CAGR »
|
$24,756.36 6,350 shares |
5-20-2019 Insider Buy |
Michael J. Valentino Executive Chairman |
$5.60
CAGR »
|
$248,662.40 44,404 shares |
12-27-2018 Insider Buy |
Park West Asset Management LLC >10% Owner |
$1.00
CAGR »
|
$397,495.00 397,495 shares |
6-14-2017 Insider Buy |
David Emerson Jorden Acting Chief Financial Officer |
$6.88
CAGR »
|
$224,998.12 32,727 shares |
6-14-2017 Insider Buy |
Michael J. Valentino Executive Chairman |
$6.88
CAGR »
|
$200,000.62 29,091 shares |
6-14-2017 Insider Buy |
Gary L. Mossman Chief Operating Officer |
$6.88
CAGR »
|
$50,001.88 7,273 shares |
Also See: Institutional Holders of PLXP
Also See: SEC filings
Below we present the annualized performance delivered by PLx Pharma stock since 3-15-2022 (the date of the most recent
insider purchase). The performance of the investment from the time PLx Pharma insider buying occurred is the ultimate
test of whether insiders were right about PLXP being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
03/16/2022 |
|
End date: |
04/13/2023 |
|
Start price/share: |
$3.93 |
|
End price/share: |
$0.04 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-98.88% |
|
Average Annual Total Return: |
-98.46% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$111.81 |
|
Years: |
1.08 |
|
PLx Pharma Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent PLx Pharma insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding PLXP
|
|